Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 short- versus long-term treatment for prevention of respiratory infections in young children with wheezing lower respiratory illness
2022-000886-42Phase 4Active
- Sponsor
- OM Pharma
- Start
- Jul 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of om-85 in Airways Infection and pulmonary infection (3 arms), sponsored by OM Pharma. Primary endpoint: Primary efficacy endpoint. Started Jul 2022; status: active.
02
Drugs
om-85
03
Conditions
Airways Infectionpulmonary infection
Beyond the preview
Go deeper on 2022-000886-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000886-42.